Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? MJE Marshall, RJ Stopforth, MS Cragg Frontiers in immunology 8, 289045, 2017 | 162 | 2017 |
New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B) A Roghanian, RJ Stopforth, LN Dahal, MS Cragg Journal of leukocyte biology 103 (6), 1077-1088, 2018 | 36 | 2018 |
Regulation of monoclonal antibody immunotherapy by FcγRIIB RJ Stopforth, KLS Cleary, MS Cragg Journal of clinical immunology 36, 88-94, 2016 | 23 | 2016 |
Shaving is an epiphenomenon of type I and II anti-CD20–mediated phagocytosis, whereas antigenic modulation limits type I monoclonal antibody efficacy LN Dahal, CY Huang, RJ Stopforth, A Mead, K Chan, JX Bowater, ... The Journal of Immunology 201 (4), 1211-1221, 2018 | 22 | 2018 |
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy K Hussain, R Liu, RCG Smith, KTJ Müller, M Ghorbani, S Macari, ... Journal of Experimental & Clinical Cancer Research 41 (1), 131, 2022 | 11 | 2022 |
The role of antigen presentation in tumor-associated macrophages RJ Stopforth, ES Ward Critical Reviews™ in Immunology 40 (3), 2020 | 11 | 2020 |
Detection of experimental and clinical immune complexes by measuring SHIP-1 recruitment to the inhibitory FcγRIIB RJ Stopforth, RJ Oldham, AL Tutt, P Duriez, HT Chan, BF Binkowski, ... The Journal of Immunology 200 (5), 1937-1950, 2018 | 10 | 2018 |
Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. 2017; 8: 1245 MJE Marshall, RJ Stopforth, MS Cragg | 3 | 2017 |
The development of a CD32C reporter assay for the study of monoclonal antibody-CD32B interactions RJ Stopforth, MS Cragg IMMUNOLOGY 143, 129-130, 2014 | | 2014 |